This content is from: Premium
Biopharma Funds Are Still Embracing VC
The number of deals is down from last year, but most firms have still been fairly active in the private markets.
Biopharma-focused hedge funds have cut back sharply on their private venture capital investments in 2022, but not to the extent of the tech-focused firms. Yes, they all participated in fewer private fundraisings this year than they have in the past. But after a big
To continue reading, subscribe now to Premium Journalism. Already a subscriber? Login.